About
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines to help people with a range of oncologic and dermatologic diseases. The companys technology targets the VDAC/HK2 system unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. Vidacs lead drug, VDA-1102, has successfully completed a phase 2b clinical trial in actinic keratosis (AK) as an investigational new drug under the FDA and is currently in a phase 2a clinical trial in CTCL in Israel. The company is also developing VDA-1275, a potent small-molecule new chemical entity that selectively modulates the novel VDAC/HK2 mechanism of action. It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for the VDAC/HK2 system over the VDAC/HK1 system. VDA-1275 is chemically unrelated to VDA-1102 and presents a different set of pharmacokinetic characteristics. It is being developed as a systemic drug for the treatment of solid tumors. Vidac was founded by Professor Max Herzberg. The company has licensed part of its technology from Tel Aviv University and Ben Gurion University.
Funding history · 1 round · $9.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Vidac Pharma become a public company and on which exchange?
- Vidac Pharma became public on the Hamburg Stock Exchange in March 2023.
- What was Vidac Pharma's last reported funding round and who were some of the investors?
- Vidac Pharma's last reported funding round was a $9 million Series A in June 2016. Investors included Mivtach Shamir Holdings and Israel Biotech Fund. For a full financing history, please refer to startupim.
- What is the current status of Vidac Pharma's lead drug, VDA-1102, in clinical trials?
- Vidac Pharma's lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial for actinic keratosis under the FDA and is currently in a Phase 2a clinical trial for CTCL in Israel.
- What is Vidac Pharma's next-generation drug candidate and its intended use?
- Vidac Pharma is developing VDA-1275, a small-molecule new chemical entity, as a systemic drug for the treatment of solid tumors.
- Which universities has Vidac Pharma licensed technology from?
- Vidac Pharma has licensed part of its technology from Tel Aviv University and Ben Gurion University.
- What recent patent was granted to Vidac Pharma in the U.S. in September 2024?
- In September 2024, the U.S. granted Vidac Pharma a patent offering broad protection of the mode of action underlying its oncology drug candidates.
- What was the outcome of Vidac Pharma's interim Phase 2a data for VDA-1102 in CTCL, reported in January 2024?
- In January 2024, Vidac Pharma reported positive interim Phase 2a data for its lead asset VDA-1102 in the orphan disease cutaneous T-cell lymphoma (CTCL).
- What clinical study is Vidac Pharma planning for VDA-1102 in actinic keratosis?
- In December 2023, Vidac Pharma announced plans to conduct a Phase 2b study for its actinic keratosis therapeutic candidate VDA-1102 with CentroDerm.